Ilani, T., D. Ben-Shachar, et al. (2001). "A peripheral marker
for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood
lymphocytes." Proc Natl Acad Sci U S A98(2): 625-8.
Dopamine is a major neurotransmitter in the central nervous system, and its
receptors are associated with a number of neuropathological disorders such as
Parkinson's disease and schizophrenia. Although the precise pathophysiology of
schizophrenia remains unknown, the dopaminergic hypothesis of the illness
assumes that the illness results from excessive activity at dopamine synapses in
the brain. Because, at present, the diagnosis of schizophrenia relies on
descriptive behavioral and symptomatic information, a peripheral measurable
marker may enable a simpler, more rapid, and more accurate diagnosis and
monitoring. In recent years, human peripheral blood lymphocytes have been found
to express several dopamine receptors (D(3), D(4), and D(5)) by using molecular
biology techniques and binding assays. It has been suggested that these dopamine
receptors found on lymphocytes may reflect receptors found in the brain. Here we
demonstrate a correlation between the D(3) dopamine receptor on lymphocytes and
schizophrenia and show a significant elevation of at least 2-fold in the mRNA
level of the D(3), but not of the D(4), dopamine receptor in schizophrenic
patients. This increase is not affected by different antipsychotic drug
treatments (typical or atypical). Moreover, nonmedicated patients exhibit the
same pattern, indicating that this change is not a result of medical treatment.
We propose the D(3) receptor mRNA on blood lymphocytes as a marker for
identification and followup of schizophrenia.
Wang, J., Z. L. Liu, et al. (2001). "Dopamine D5 receptor gene polymorphism and
the risk of levodopa-induced motor fluctuations in patients with Parkinson's
disease." Neurosci Lett308(1): 21-4.
Motor fluctuations are the most common complication of levodopa therapy for
Parkinson's disease (PD). Genetic factors could play a role in determining the
occurrence of motor fluctuations. To investigate whether dopamine receptor D5
(DRD5) T978C polymorphism is associated with the risk of developing motor
fluctuations in PD, we studied this polymorphism in a case-control study of 120
subjects with sporadic PD and 110 control subjects. We found that the overall
allelic and genotypic frequencies did not differ significantly between patients
with PD and control subjects (all P>0.7), and between motor fluctuators (n=50)
and non-motor fluctuators (n=50) (all P>0.8). It suggests that DRD5 T978C
polymorphism is not associated with the susceptibility to PD, nor with the risk
of developing motor fluctuations in PD. Therefore, other polymorphisms that
alter the expression of the dopamine receptors should be further studied.